- Home
- LPCN vs USBC Comparison
LPCN vs USBC Comparison
Compare LPCN & USBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- USBC
- Stock Information
- Founded
- LPCN 1997
- USBC N/A
- Country
- LPCN United States
- USBC
- Employees
- LPCN N/A
- USBC N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- USBC
- Sector
- LPCN Health Care
- USBC
- Exchange
- LPCN Nasdaq
- USBC Nasdaq
- Market Cap
- LPCN 16.1M
- USBC 14.5M
- IPO Year
- LPCN N/A
- USBC N/A
- Fundamental
- Price
- LPCN $2.89
- USBC $0.83
- Analyst Decision
- LPCN Strong Buy
- USBC
- Analyst Count
- LPCN 2
- USBC 0
- Target Price
- LPCN $9.00
- USBC N/A
- AVG Volume (30 Days)
- LPCN 16.1K
- USBC N/A
- Earning Date
- LPCN 11-06-2025
- USBC N/A
- Dividend Yield
- LPCN N/A
- USBC N/A
- EPS Growth
- LPCN N/A
- USBC N/A
- EPS
- LPCN N/A
- USBC N/A
- Revenue
- LPCN $4,208,119.00
- USBC N/A
- Revenue This Year
- LPCN N/A
- USBC N/A
- Revenue Next Year
- LPCN N/A
- USBC N/A
- P/E Ratio
- LPCN N/A
- USBC N/A
- Revenue Growth
- LPCN N/A
- USBC N/A
- 52 Week Low
- LPCN $2.68
- USBC N/A
- 52 Week High
- LPCN $6.17
- USBC N/A
- Technical
- Relative Strength Index (RSI)
- LPCN 39.07
- USBC N/A
- Support Level
- LPCN $2.86
- USBC N/A
- Resistance Level
- LPCN $3.00
- USBC N/A
- Average True Range (ATR)
- LPCN 0.12
- USBC 0.00
- MACD
- LPCN -0.01
- USBC 0.00
- Stochastic Oscillator
- LPCN 12.28
- USBC 0.00
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.